Drugs / ALX-0651
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01374503 | Jun 2011 → Jan 2012 | — | Ablynx, a Sanofi company | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALX-0651 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01374503 ↗ |
| Action | Inhibit | “CXCR4-inhibitor ALX-0651” NCT01374503 ↗ |
| Modality | Protein / enzyme biologic | “First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4” NCT01374503 ↗ |
| Route | Intravenous | “Administered Intravenously to Healthy Male Volunteers” NCT01374503 ↗ |
| Target | CXCR4 | “First in Man Study of ALX-0651, a Nanobody Inhibiting CXCR4” NCT01374503 ↗ |